A case-control study on factor V Leiden: an independent, gender-dependent risk factor for venous thromboembolism

Abstract Background Activated protein C resistance (APCR) due to factor V Leiden (FVL) mutation (R506Q) is a major risk factor in patients with venous thromboembolism (VTE). The present study investigated the clinical manifestations and the risk of venous thromboembolism regarding multiple clinical,...

Full description

Saved in:

Bibliographic Details
Published in:	Thrombosis journal Vol. 19; no. 1; p. 74
Main Authors:	Takhviji, Vahideh, Zibara, Kazem, Maleki, Asma, Azizi, Ebrahim, Hommayoun, Sanaz, Tabatabaei, Mohammadreza, Ahmadi, Seyed Esmaeil, Soleymani, Maral, Ghalesardi, Omid Kiani, Farokhian, Mina, Davari, Afshin, Paridar, Pouria, Kalantari, Anahita, Khosravi, Abbas
Format:	Journal Article
Language:	English
Published:	London BioMed Central Ltd 19-10-2021 BioMed Central BMC
Subjects:	APCR Clopidogrel DVT Factor V Leiden Oral contraceptives Protein C Pulmonary embolism Risk factors Thromboembolism Thrombophilia Venous thromboembolism Iran
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Abstract Background Activated protein C resistance (APCR) due to factor V Leiden (FVL) mutation (R506Q) is a major risk factor in patients with venous thromboembolism (VTE). The present study investigated the clinical manifestations and the risk of venous thromboembolism regarding multiple clinical, laboratory, and demographic properties in FVL patients. Material and methods A retrospective cross-sectional analysis was conducted on a total of 288 FVL patients with VTE according to APCR. In addition, 288 VET control samples, without FVL mutation, were also randomly selected. Demographic information, clinical manifestations, family and treatment history were recorded, and specific tests including t-test, chi-square and uni- and multi-variable regression tests applied. Results APCR was found to be 2.3 times significantly more likely in men (OR: 2.1, p < 0.05) than women. The risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in APCR patients was 4.5 and 3.2 times more than the control group, respectively ( p < 0.05). However, APCR could not be an independent risk factor for arterial thrombosis (AT) and pregnancy complications. Moreover, patients were evaluated for thrombophilia panel tests and showed significantly lower protein C and S than the control group and patients without DVT ( p < 0.0001). Conclusion FVL mutation and APCR abnormality are noticeable risk factors for VTE. Screening strategies for FVL mutation in patients undergoing surgery, oral contraceptive medication, and pregnancy cannot be recommended, but a phenotypic test for activated protein C resistance should be endorsed in patients with VTE.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1477-9560 1477-9560
DOI:	10.1186/s12959-021-00328-0